Felixvet Receives FDA Approval for Cefpodoxime Proxetil Tablets

Kansas City, Mo. — October 30, 2025 — Felixvet is dedicated to advancing veterinary care and addressing the needs of veterinarians, pet owners and distributors. To further this commitment, Felixvet is now introducing Cefpodoxime Proxetil tablets, an antimicrobial indicated for the treatment of skin infections in dogs. Felixvet, Inc., a manufacturer based in Ireland of generic pharmaceuticals for companion animals,  established its North American headquarters in Kansas City, Missouri, in 2023.

“Felixvet is committed to providing affordable options without sacrificing quality or reliability,” said Vince Palasota, President of North America at Felixvet. “We adhere to rigorous FDA standards, ensuring safety and efficacy in every product.”

Cefpodoxime Proxetil is a broad-spectrum antibiotic, effective against a wide variety of bacteria. It is primarily prescribed for the treatment of skin infections in dogs, such as those caused by Staphylococcus and Streptococcus bacteria. It works by interfering with the production of bacterial cell walls, ultimately killing vulnerable bacteria. Cefpodoxime Proxetil is a third-generation cephalosporin, meaning it has a wider range of efficacy as compared to previous generations. 

Cefpodoxime Proxetil is easy to administer, with its single daily dosing. It is available in 100 mg and 200 mg tablets and is intended for oral use in dogs only. 

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, contact info@felixvetus.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com